226 related articles for article (PubMed ID: 8133143)
1. The ret/PTC oncogene in papillary thyroid carcinoma.
Jhiang SM; Mazzaferri EL
J Lab Clin Med; 1994 Mar; 123(3):331-7. PubMed ID: 8133143
[No Abstract] [Full Text] [Related]
2. Targeted expression of the ret/PTC1 oncogene induces papillary thyroid carcinomas.
Jhiang SM; Sagartz JE; Tong Q; Parker-Thornburg J; Capen CC; Cho JY; Xing S; Ledent C
Endocrinology; 1996 Jan; 137(1):375-8. PubMed ID: 8536638
[TBL] [Abstract][Full Text] [Related]
3. Low rate of ret proto-oncogene activation (PTC/retTPC) in papillary thyroid carcinomas from Saudi Arabia.
Zou M; Shi Y; Farid NR
Cancer; 1994 Jan; 73(1):176-80. PubMed ID: 8275421
[TBL] [Abstract][Full Text] [Related]
4. High frequency of rearrangement of the RET protooncogene (RET/PTC) in Chinese papillary thyroid carcinomas.
Lee CH; Hsu LS; Chi CW; Chen GD; Yang AH; Chen JY
J Clin Endocrinol Metab; 1998 May; 83(5):1629-32. PubMed ID: 9589668
[TBL] [Abstract][Full Text] [Related]
5. Different significance of ret/PTC(1) and ret/PTC(3) rearrangements in thyroid carcinogenesis: lesson from two subgroups of patients with papillary thyroid carcinomas showing the highest incidence of ret/PTC activation.
Cetta F; Gori M; Montalto G; Zuckermann M; Toti P
J Clin Endocrinol Metab; 2001 Mar; 86(3):1429. PubMed ID: 11238550
[No Abstract] [Full Text] [Related]
6. RET/PTC oncogene activation is an early event in thyroid carcinogenesis.
Viglietto G; Chiappetta G; Martinez-Tello FJ; Fukunaga FH; Tallini G; Rigopoulou D; Visconti R; Mastro A; Santoro M; Fusco A
Oncogene; 1995 Sep; 11(6):1207-10. PubMed ID: 7566982
[TBL] [Abstract][Full Text] [Related]
7. Breakpoint characterization of the ret/PTC oncogene in human papillary thyroid carcinoma.
Smanik PA; Furminger TL; Mazzaferri EL; Jhiang SM
Hum Mol Genet; 1995 Dec; 4(12):2313-8. PubMed ID: 8634704
[TBL] [Abstract][Full Text] [Related]
8. RET/PTC oncogene activation defines a subset of papillary thyroid carcinomas lacking evidence of progression to poorly differentiated or undifferentiated tumor phenotypes.
Tallini G; Santoro M; Helie M; Carlomagno F; Salvatore G; Chiappetta G; Carcangiu ML; Fusco A
Clin Cancer Res; 1998 Feb; 4(2):287-94. PubMed ID: 9516913
[TBL] [Abstract][Full Text] [Related]
9. Ret oncogene activation in human thyroid neoplasms is restricted to the papillary cancer subtype.
Santoro M; Carlomagno F; Hay ID; Herrmann MA; Grieco M; Melillo R; Pierotti MA; Bongarzone I; Della Porta G; Berger N
J Clin Invest; 1992 May; 89(5):1517-22. PubMed ID: 1569189
[TBL] [Abstract][Full Text] [Related]
10. [Rearrangement of the RET gene in papillary thyroid carcinoma].
Wiench M; Włoch J; Oczko M; Gubała E; Jarzab B
Wiad Lek; 2001; 54 Suppl 1():64-71. PubMed ID: 12182064
[TBL] [Abstract][Full Text] [Related]
11. RET/PTC rearrangement in thyroid tumors.
Nikiforov YE
Endocr Pathol; 2002; 13(1):3-16. PubMed ID: 12114746
[TBL] [Abstract][Full Text] [Related]
12. Identification of the product of two oncogenic rearranged forms of the RET proto-oncogene in papillary thyroid carcinomas.
Lanzi C; Borrello MG; Bongarzone I; Migliazza A; Fusco A; Grieco M; Santoro M; Gambetta RA; Zunino F; Della Porta G
Oncogene; 1992 Nov; 7(11):2189-94. PubMed ID: 1437145
[TBL] [Abstract][Full Text] [Related]
13. The ret/ptc1 oncogene is activated in familial adenomatous polyposis-associated thyroid papillary carcinomas.
Cetta F; Chiappetta G; Melillo RM; Petracci M; Montalto G; Santoro M; Fusco A
J Clin Endocrinol Metab; 1998 Mar; 83(3):1003-6. PubMed ID: 9506763
[TBL] [Abstract][Full Text] [Related]
14. RET rearrangements in familial papillary thyroid carcinomas.
Corvi R; Lesueur F; Martinez-Alfaro M; Zini M; Decaussin M; Murat A; Romeo G
Cancer Lett; 2001 Sep; 170(2):191-8. PubMed ID: 11463498
[TBL] [Abstract][Full Text] [Related]
15. ret/PTC-1, -2, and -3 oncogene rearrangements in human thyroid carcinomas: implications for metastatic potential?
Mayr B; Brabant G; Goretzki P; Rüschoff J; Dietmaier W; Dralle H
J Clin Endocrinol Metab; 1997 Apr; 82(4):1306-7. PubMed ID: 9100614
[No Abstract] [Full Text] [Related]
16. Correspondence re: G. Tallini et al., RET/PTC oncogene activation defines a subset of papillary thyroid carcinomas lacking evidence of progression to poorly differentiated or undifferentiated tumor phenotype. Clin. Cancer Res., 4:287-294, 1998.
Soares P; Sobrinho-Simões M
Clin Cancer Res; 1999 Nov; 5(11):3724-5. PubMed ID: 10589793
[No Abstract] [Full Text] [Related]
17. Prevalence and distribution of ret/ptc 1, 2, and 3 in papillary thyroid carcinoma in New Caledonia and Australia.
Chua EL; Wu WM; Tran KT; McCarthy SW; Lauer CS; Dubourdieu D; Packham N; O'Brien CJ; Turtle JR; Dong Q
J Clin Endocrinol Metab; 2000 Aug; 85(8):2733-9. PubMed ID: 10946873
[TBL] [Abstract][Full Text] [Related]
18. Lack of PTC gene (ret proto-oncogene rearrangement) in human thyroid tumors.
Namba H; Yamashita S; Pei HC; Ishikawa N; Villadolid MC; Tominaga T; Kimura H; Tsuruta M; Yokoyama N; Izumi M
Endocrinol Jpn; 1991 Dec; 38(6):627-32. PubMed ID: 1823030
[TBL] [Abstract][Full Text] [Related]
19. Molecular characterization of RET/PTC3; a novel rearranged version of the RETproto-oncogene in a human thyroid papillary carcinoma.
Santoro M; Dathan NA; Berlingieri MT; Bongarzone I; Paulin C; Grieco M; Pierotti MA; Vecchio G; Fusco A
Oncogene; 1994 Feb; 9(2):509-16. PubMed ID: 8290261
[TBL] [Abstract][Full Text] [Related]
20. High prevalence of RET proto-oncogene activation (RET/PTC) in papillary thyroid carcinomas.
Lam KY; Lo CY; Leung PS
Eur J Endocrinol; 2002 Dec; 147(6):741-5. PubMed ID: 12457448
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
